Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients who’ve undergone PCI seems to reduce MACCE compared with aspirin monotherapy ...
The efficacy of P2Y12 monotherapy depends on the type of drug used after discontinuation of dual antiplatelet therapy (DAPT) for post-PCI patients, according to a new patient-level meta-analysis.
Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high risk for ...
Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...
Madrid, Spain – 31 August 2025: Among low-risk patients with acute MI who underwent early complete revascularisation and received one month of dual antiplatelet therapy (DAPT), P2Y12 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results